Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1984 Nov 1;160(5):1375–1389. doi: 10.1084/jem.160.5.1375

Identification of the Raji cell membrane-derived C1q inhibitor as a receptor for human C1q. Purification and immunochemical characterization

PMCID: PMC2187510  PMID: 6436431

Abstract

We have shown previously that an activity which is capable of precipitating purified C1q and inhibiting some of the C1q-dependent biologic reactions could be solubilized from the membranes of both normal human peripheral B lymphocytes and a B cell-derived lymphoblastoid cell line (Raji), both of which are known to possess receptors for human C1q. In this report we present evidence that this membrane-associated C1q inhibitor is a chondroitinase-insensitive macromolecule and is the receptor for human C1q. The receptor was solubilized from membranes of Raji cells with Nonidet P-40 and purified to homogeneity using C1q-Sepharose 4B affinity chromatography. Equilibrium density gradient centrifugation analysis revealed that the complex could be resolved into a protein-rich, low density fraction and a carbohydrate-rich, high density fraction. The large hydrodynamic size, coupled with the high buoyant density, suggests that a proteoglycan is a constituent of the complex and indicates that the receptor might be a macromolecular complex of a proteoglycan portion noncovalently linked to a 60-70 kD glycoprotein. The glycoprotein moiety, in turn, consists of two or more identical (70,000 mol wt) polypeptide chains held together by disulfide bonds and constitutes the C1q receptor (C1qR). Sucrose density ultracentrifugation analysis showed that the isolated receptor sediments with an apparent rate of 4.2 S. Immunochemical analyses demonstrated that a typical preparation of the C1qR complex consists of approximately 23% uronic acid and approximately 21% galactosamine with a galactosamine-to-glucosamine ratio of 3.2. Binding of C1q to the receptor was found to be optimal at low ionic strength and neutral or near-neutral pH (7-7.4). The isolated receptor was found to inhibit C1q hemolytic function, abrogate C1q- dependent rosette formation, and block the C1q-dependent, cell-mediated cytotoxicity, all of which are activities mediated by the receptor.

Full Text

The Full Text of this article is available as a PDF (1.2 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Almeda S., Rosenberg R. D., Bing D. H. The binding properties of human complement component C1q. Interaction with mucopolysaccharides. J Biol Chem. 1983 Jan 25;258(2):785–791. [PubMed] [Google Scholar]
  2. Bordin S., Kolb W. P., Page R. C. C1Q receptors on cultured human gingival fibroblasts: analysis of binding properties. J Immunol. 1983 Apr;130(4):1871–1875. [PubMed] [Google Scholar]
  3. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  4. Calcott M. A., Müller-Eberhard H. J. C1q protein of human complement. Biochemistry. 1972 Aug 29;11(18):3443–3450. doi: 10.1021/bi00768a018. [DOI] [PubMed] [Google Scholar]
  5. Cazenave J. P., Assimeh S. N., Painter R. H., Pachham M. A., Mustard J. F. Clq inhibition of the interaction of collagen with human platelets. J Immunol. 1976 Jan;116(1):162–163. [PubMed] [Google Scholar]
  6. Dickler H. B., Kunkel H. G. Interaction of aggregated -globulin with B lymphocytes. J Exp Med. 1972 Jul 1;136(1):191–196. doi: 10.1084/jem.136.1.191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ford J. D., Baker J. R. Procedures for the automated analyses of proteoglycans and glycosaminoglycans. Anal Biochem. 1978 Feb;84(2):539–550. doi: 10.1016/0003-2697(78)90073-8. [DOI] [PubMed] [Google Scholar]
  8. Gabay Y., Perlmann H., Perlmann P., Sobel A. T. A rosette assay for the determination of C 1 q receptor-bearing cells. Eur J Immunol. 1979 Oct;9(10):797–801. doi: 10.1002/eji.1830091010. [DOI] [PubMed] [Google Scholar]
  9. Ghebrehiwet B. C1q inhibitor (C1qINH): functional properties and possible relationship to a lymphocyte membrane-associated C1q precipitin. J Immunol. 1981 May;126(5):1837–1842. [PubMed] [Google Scholar]
  10. Ghebrehiwet B., Hamburger M. Purification and partial characterization of a C1q inhibitor from the membranes of human peripheral blood lymphocytes. J Immunol. 1982 Jul;129(1):157–162. [PubMed] [Google Scholar]
  11. Ghebrehiwet B., Müller-Eberhard H. J. Lysis of C1Q-coated chicken erythrocytes by human lymphoblastoid cell lines. J Immunol. 1978 Jan;120(1):27–32. [PubMed] [Google Scholar]
  12. Hurst M. M., Volanakis J. E., Hester R. B., Stroud R. M., Bennett J. C. The structural basis for binding of complement by immunoglobulin M. J Exp Med. 1974 Oct 1;140(4):1117–1121. doi: 10.1084/jem.140.4.1117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kehoe J. M., Fougereau M. Immunoglobulin peptide with complement fixing activity. Nature. 1969 Dec 20;224(5225):1212–1213. doi: 10.1038/2241212a0. [DOI] [PubMed] [Google Scholar]
  14. Klein E., Klein G., Nadkarni J. S., Nadkarni J. J., Wigzell H., Clifford P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 1968 Jul;28(7):1300–1310. [PubMed] [Google Scholar]
  15. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  16. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  17. March S. C., Parikh I., Cuatrecasas P. A simplified method for cyanogen bromide activation of agarose for affinity chromatography. Anal Biochem. 1974 Jul;60(1):149–152. doi: 10.1016/0003-2697(74)90139-0. [DOI] [PubMed] [Google Scholar]
  18. PULVERTAFT J. V. A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE. J Clin Pathol. 1965 May;18:261–273. doi: 10.1136/jcp.18.3.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Porter R. R. Structure and activation of the early components of complement. Fed Proc. 1977 Aug;36(9):2191–2196. [PubMed] [Google Scholar]
  20. Porter R. R. The proteolytic enzymes of the complement system. Methods Enzymol. 1981;80(Pt 100):3–5. doi: 10.1016/s0076-6879(81)80003-1. [DOI] [PubMed] [Google Scholar]
  21. Reid K. B., Gagnon J., Frampton J. Completion of the amino acid sequences of the A and B chains of subcomponent C1q of the first component of human complement. Biochem J. 1982 Jun 1;203(3):559–569. doi: 10.1042/bj2030559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Reid K. B., Sim R. B., Faiers A. P. Inhibition of the reconstitution of the haemolytic activity of the first component of human complement by a pepsin-derived fragment of subcomponent C1q. Biochem J. 1977 Feb 1;161(2):239–245. doi: 10.1042/bj1610239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Shelton E., Yonemasu K., Stroud R. M. Ultrastructure of the human complement component, Clq (negative staining-glutamine synthetase-biologically active Clq). Proc Natl Acad Sci U S A. 1972 Jan;69(1):65–68. doi: 10.1073/pnas.69.1.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Silvestri L., Baker J. R., Rodén L., Stroud R. M. The C1q inhibitor in serum is a chondroitin 4-sulfate proteoglycan. J Biol Chem. 1981 Jul 25;256(14):7383–7387. [PubMed] [Google Scholar]
  25. Sim R. B., Arlaud G. J., Colomb M. G. C1 inhibitor-dependent dissociation of human complement component C1 bound to immune complexes. Biochem J. 1979 Jun 1;179(3):449–457. doi: 10.1042/bj1790449a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Suba E. A., Csako G. C1q (c1) receptor on human platelets: inhibition of collagen-induced platelet aggregation by C1q (C1) molecules. J Immunol. 1976 Jul;117(1):304–309. [PubMed] [Google Scholar]
  27. Sundqvist K. G., Svehag S. E., Thorstensson R. T. Dynamic aspects of the interaction between antibodies and complement at the cell surface. Scand J Immunol. 1974;3(3):237–250. doi: 10.1111/j.1365-3083.1974.tb01254.x. [DOI] [PubMed] [Google Scholar]
  28. Tenner A. J., Cooper N. R. Analysis of receptor-mediated C1q binding to human peripheral blood mononuclear cells. J Immunol. 1980 Oct;125(4):1658–1664. [PubMed] [Google Scholar]
  29. Wautier J. L., Reid K. B., Legrand Y., Caen J. P. Region of the Clq molecule involved in the interaction between platelets and subcomponent Clq of the first component of complement. Mol Immunol. 1980 Nov;17(11):1399–1405. doi: 10.1016/0161-5890(80)90009-7. [DOI] [PubMed] [Google Scholar]
  30. Yonemasu K., Stroud R. M. Clq: rapid purification method for preparation of monospecific antisera and for biochemical studies. J Immunol. 1971 Feb;106(2):304–313. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES